To validate the prognostic value of the risk score for immunotherapy sensitivity, we used two external datasets (GSE135222, GSE126044) containing information from patients with NSCLC treated with anti-PD-1/PD-L1 therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.